摘要
[目的]探讨血清N-乙酰神经氨酸(Neu5Ac)及S100钙结合蛋白A1(S100A1)水平预测急性脑梗死(ACI)患者预后的作用.[方法]选择2021年8月—2022年8月间长葛市人民医院收治的80例ACI患者纳入研究组,根据病情分为轻度组(n=35)、中度型(n=30)和重度组(n=15),根据治疗后3个月的随访结果分为预后良好组(n=54)和预后不良组(n=26);另选择同时期行体格检查的70例健康者纳入对照组.所有研究对象均在入院后24 h内检测血清Neu5Ac、S100A1水平,并进行组间比较;采用受试者工作特征曲线(ROC)评估ACI患者预后临床效能.[结果]研究组血清Neu5Ac、S100A1水平均明显高于对照组(P<0.05);重度组血清Neu5Ac、S100A1水平明显高于中度组和轻度组(重度组>中度组>轻度组,P<0.05);预后不良组血清Neu5Ac、S100A1水平均明显高于预后良好组(P<0.05);血清Neu5Ac、S100A1预测ACI预后的AUC分别为0.830和0.882,二者联合预测的AUC为0.927.[结论]ACI患者血清Neu5Ac、S100A1水平均明显升高,其水平变化与病情及预后密切相关,两者联合应用预测ACI预后的效果更佳.
OBJECTIVE To explore the clinical efficacy of serum N-acetylneuramic acid(Neu5Ac)and S100 calcbinding protein A1(S100A1)levels in predicting prognosis of cases with acute cerebral infarction(ACI).METHODS Eighty cases with ACI from August 2021 to August 2022 were selected as the study group,and were divided into mild group(n=35),moderate group(n=30)and severe group(n=15).The cases were divided into good prognosis group(n=54)and bad prognosis group(n=26)according to the follow-up 3 months after treatment.Another 70 healthy subjects were selected as control group.The serum levels of Neu5Ac and S100A1 were detected within 24h after admission.ROC was used to evaluate the diagnostic value of serum Neu5Ac and S100A1 in the prognosis of cases with ACI.RESULTS Serum levels of Neu5Ac and S100A1 in study group were higher compared with control group(P<0.05).Serum levels of Neu5Ac and S100A1 in severe group were higher than those in moderate group and mild group(severe group>moderate group>mild group,P<0.05).Serum levels of Neu5Ac and S100A1 in cases with acute cerebral infarction with poor prognosis were higher than those in good prognosis group(P<0.05).The AUC of serum Neu5Ac and S100A1 for predicting the prognosis of ACI was 0.830 and 0.882,The AUC of combined were 0.927.CONCLUSION Serum Neu5Ac and S100A1 levels increased in cases with ACI,and their changes were closely related to the condition and prognosis,and the combination had higher clinical efficacy in predicting prognosis of the disease.
作者
闫伟立
刘葛霞
YAN Weili;LIU Gexia(Department of Neurology,Changge Cit y People’s Hospital,Changge 461500,Henan,China)
出处
《延边大学医学学报》
CAS
2024年第2期144-147,共4页
Journal of Medical Science Yanbian University
